Loading stock data…
PROF
$6.86+0.16 (+2.39%)
Market ClosedLast close May 1
Profound Medical Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Profound Medical Corp. in the Healthcare sector is trading at $6.86. The stock is currently 23% below its 52-week high of $8.95, remaining 10.6% above its 200-day moving average. Technical signals show neutral RSI of 62 and bullish MACD crossover, explaining why PROF maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 62) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.86
Potential Upside
5%
Whystock Fair Value$7.20
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO sy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$244.98M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-64.08%
Volume
Today's trading volume
63,333
Recent News
Indivior Pharmaceuticals Inc. (INDV) Q1 Earnings and Revenues Beat Estimates
Indivior Pharmaceuticals Inc. (INDV) delivered earnings and revenue surprises of +50.78% and +18.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical Showcases TULSA Data, AI Software Upgrades, and Reimbursement Tailwinds at Conference
Profound Medical (NASDAQ:PROF) highlighted what it described as growing clinical evidence, expanding software capabilities, and improving reimbursement dynamics for its MRI-guided “incision-free” ultrasound platform during a conference presentation led by Arun, a company executive who said he has be
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Profound Medical reports CAPTAIN trial meets primary safety endpoint
Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic radical prostatectomy in men with organ-confined, intermediate-risk, Gleason Score 7 prostate cancer. CAPTAIN exceeded its enrollment target, treating 211 patients, instead of the initially planned 201 patients, by August 2025 at 20 sites in the United States, two in Canada and one in Europe. Baseline
Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
Profound Medical Corp (PROF) reports a 43% revenue increase and global expansion, while addressing operational challenges and aiming for cash flow positivity.